ITC Excludes CT Imaging Module in 337 Ruling

On June 1, 2026, the U.S. International Trade Commission issued its final determination in Investigation No. 337-TA-1483, finding that a “dynamic photon-counting calibration module” used in certain photon-counting CT equipment exported to the United States by a Chinese enterprise infringed MolecuLight Inc.’s U.S. Patent No. US10438356. The resulting limited exclusion order, effective immediately, is particularly relevant to medical imaging equipment manufacturers, CT system exporters, spare-parts suppliers, U.S. market distributors, and compliance teams because it directly affects the entry of related systems and replacement modules into the U.S. market.

Event Overview

On June 1, 2026, the U.S. International Trade Commission made a final determination in Investigation No. 337-TA-1483. According to the available information, the ITC determined that the “dynamic photon-counting calibration module” used in certain photon-counting CT equipment exported to the United States by a Chinese enterprise infringed Canadian company MolecuLight Inc.’s U.S. Patent No. US10438356.

The module at issue is related to image noise suppression and spectral reconstruction algorithms. Following the final determination, the ITC issued a limited exclusion order. The order took effect immediately, and the relevant complete systems and spare parts containing the excluded module may no longer enter the U.S. market.

At present, the publicly available information identifies the case number, the patent number, the affected module, the nature of the exclusion order, and the immediate effect of the import restriction. No additional verified details are available in the provided information regarding the named Chinese enterprise, the full scope of affected product models, or any subsequent remedial measures.

Which Segments of the Industry Are Affected

Medical Imaging Equipment Exporters

Exporters of photon-counting CT equipment to the United States are the most directly affected because the limited exclusion order applies to relevant complete systems and spare parts containing the identified module. The impact is mainly reflected in import clearance risk, contract delivery uncertainty, and the need to determine whether shipped or planned products include the restricted image-processing module.

From an industry perspective, this decision makes patent and module-level compliance more important for companies exporting advanced medical imaging systems to the U.S. market. The affected component is not described as a basic hardware accessory, but as a module tied to image noise suppression and spectral reconstruction algorithms, which means compliance review may need to cover embedded software, algorithmic functions, and system integration rather than only external device specifications.

CT System Manufacturers and Integration Teams

Manufacturers and integration teams involved in photon-counting CT systems may be affected if their product architecture relies on the same or similar dynamic photon-counting calibration function for image processing. The order concerns a specific module, but complete systems containing that module are also barred from entering the U.S. market.

Analysis shows that the practical issue for manufacturers is not limited to whether the final CT product is listed in a sales catalog. They may need to review how image-processing modules are designed, sourced, documented, and embedded in the system. Any uncertainty around whether a module falls within the scope of the exclusion order could create operational pressure before products are exported to the United States.

Spare-Parts and After-Sales Service Suppliers

Spare-parts suppliers are also affected because the available information states that relevant spare parts may no longer enter the U.S. market. This matters for companies providing maintenance, replacement, and after-sales support for photon-counting CT systems that use the excluded module.

Observably, the impact may appear not only in new equipment sales but also in service continuity. If replacement modules or related parts are restricted from import, service providers may need to verify whether existing maintenance commitments in the United States depend on parts covered by the order. This should be treated as a compliance and supply availability issue rather than only a logistics matter.

U.S. Market Distributors and Channel Operators

Distributors and channel operators serving U.S. hospitals, imaging centers, or medical equipment procurement channels may face uncertainty if their portfolios include affected photon-counting CT systems or related replacement parts. The immediate effectiveness of the limited exclusion order means import planning and inventory communication may require prompt review.

What is more worth noting now is that channel operators may need to distinguish between products already in the market and products still awaiting import. Based on the provided information, the order concerns entry into the U.S. market for relevant complete systems and spare parts. Companies should avoid assuming that all products under the same equipment category are affected unless the module and product scope are confirmed.

Supply Chain, Compliance, and Procurement Teams

Supply chain and procurement teams connected to medical imaging equipment production may be affected because the restricted module involves image noise suppression and spectral reconstruction algorithms. Procurement teams may need to check whether sourced modules, software functions, or integrated components are connected to the patent issue identified in the ITC determination.

From an industry perspective, the case highlights the need for closer coordination among engineering, procurement, legal, and export teams. The key business risk is that a module-level patent issue can affect the market entry of complete medical imaging systems and spare parts, especially when the order takes effect immediately.

Key Points for Companies and Practitioners to Monitor and Respond To

Review Whether Products or Spare Parts Contain the Identified Module

Companies involved in photon-counting CT equipment exports to the United States should first determine whether their systems or spare parts contain the “dynamic photon-counting calibration module” identified in the ITC determination. This review should focus on the actual image-processing function, including image noise suppression and spectral reconstruction elements, rather than relying only on product names or equipment categories.

It is better understood as a product-scope verification task. Before arranging new U.S.-bound shipments, companies should confirm whether the relevant module is present, whether it is part of a complete system, and whether replacement parts could fall within the limited exclusion order.

Track Further Official Clarification on Scope and Implementation

Companies should continue to monitor official statements or implementation details related to Investigation No. 337-TA-1483, including any clarification on the scope of the limited exclusion order. The currently provided information confirms the final determination, the patent involved, the excluded module, and the immediate effect of the import restriction, but does not provide a full list of affected models or parties.

Analysis shows that the distinction between a general policy signal and an enforceable import restriction is important in this case. The limited exclusion order is already effective, but companies still need to follow official scope interpretation to avoid overextending or underestimating the business impact.

Separate U.S.-Bound Business From Other Market Plans

Because the order concerns entry into the U.S. market, companies should separately assess U.S.-bound shipments, U.S. service parts, and U.S. customer commitments. Products intended for other markets should not automatically be treated as affected based only on the information provided, but any product using the same module may still require internal review before future U.S. business planning.

From an industry perspective, this is a market-specific compliance issue with direct operational consequences. Exporters, distributors, and after-sales service providers should update internal shipment approval procedures for U.S.-bound complete systems and spare parts that may include the module.

Prepare Communication Plans for Customers and Supply Partners

Companies with pending U.S. deliveries or after-sales obligations should prepare factual communication for customers, logistics partners, and service teams. The communication should avoid speculation and should focus on confirmed points: the ITC final determination date, the affected module, the patent number, the limited exclusion order, and the immediate restriction on relevant complete systems and spare parts entering the U.S. market.

What is more worth noting now is the need to prevent inconsistent messages across sales, compliance, and service departments. If product scope is still being verified internally, companies should state that verification is underway rather than presenting unconfirmed conclusions as final.

Editor’s View / Industry Observation

Observably, this ITC ruling is not merely a routine legal update for the medical device sector. It shows how a patent dispute involving a specific image-processing module can affect the import status of complete photon-counting CT systems and replacement parts. For companies operating in advanced medical imaging, module-level intellectual property risk can become a market-access issue when it is tied to a Section 337 exclusion order.

Analysis shows that the event has already formed a concrete result for the identified module because the limited exclusion order is effective immediately. At the same time, it also functions as a broader signal for the industry: product compliance review for medical imaging equipment should include embedded algorithms, calibration functions, and software-linked modules, not only visible hardware components.

From an industry perspective, continued attention is necessary because the currently available information does not disclose all commercial details, including the complete list of affected product models or any later response from the companies involved. Businesses connected to U.S.-bound photon-counting CT equipment should therefore treat the matter as both an active import restriction and a compliance signal for future product review.

Conclusion

The June 1, 2026 ITC final determination in Investigation No. 337-TA-1483 carries clear industry significance for photon-counting CT equipment exporters, medical imaging system manufacturers, spare-parts suppliers, U.S. distributors, and compliance teams. The immediate exclusion of relevant complete systems and spare parts containing the identified dynamic photon-counting calibration module turns a patent finding into a practical market-entry issue.

It is better understood as an enforceable result for the products and parts covered by the limited exclusion order, while also serving as a signal that advanced medical imaging companies need more precise module-level intellectual property and import-compliance review. The most appropriate current response is to verify affected product scope, monitor official implementation details, and manage U.S.-bound shipments and customer communication with caution.

Information Source Statement

Main source: Provided event information regarding the U.S. International Trade Commission final determination in Investigation No. 337-TA-1483 dated June 1, 2026.

Key referenced details from the provided information include the ITC final determination, MolecuLight Inc.’s U.S. Patent No. US10438356, the identified dynamic photon-counting calibration module, the limited exclusion order, and the immediate restriction on relevant complete systems and spare parts entering the U.S. market.

Items requiring continued observation include any further official clarification on the scope of the limited exclusion order, the complete list of affected product models, and any subsequent response or adjustment by the companies involved.